Treatment of BM mononuclear cells of MM patients with ACY241, an HDAC6 selective inhibitor, significantly reduced the HLA-DRlow/-CD11b+CD33+ MDSC population, while it augments the immune response as evidenced by increased perforin/CD107a expression, IFN-γ/IL-2/TNF-α production and antigen-specific central memory cytotoxic T lymphocytes (68). This evidence concerns the gene CD33 and Miyoshi myopathy.